ArticlePLoS computational biology2025
Multi-view fusion based on graph convolutional network with attention mechanism for predicting miRNA related to drugs.
Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- HMHLVI: Hybrid Multi-view Hypergraph Learning with Variational Inference for snoRNA-Drug Association Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- Heterogeneous dual-channel and interpretable graph representation learning with global virtual nodes for microRNA-mediated drug sensitivity prediction.Molecular diversity · 2026Article
- A pre-trained language model-based cross-modal fusion framework for predicting miRNA-drug resistance and sensitivity associations.PLoS computational biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
MicroRNAs (miRNAs) play crucial roles in cancer progression, invasion, and response to treatment, particularly in regulating anticancer drug resistance and sensitivity. Identifying potential human miRNA-drug associations (MDAs) that manifest as resistance or sensitivity relationships offers valuable insights for cancer treatment and drug development. With the growing availability of biological data, computational methods have emerged as powerful tools to complement experimental approaches. However, limited attention has been paid to computational prediction of MDAs. Furthermore, existing approaches typically rely on known MDA information, overlooking the valuable insights available from multi-source data related to miRNAs and drugs. In this study, we present a multi-view fusion-based graph convolutional network with attention mechanism (MGCNA) to predict miRNA-associated drug resistance/sensitivity. Specifically, MGCNA integrates macro- and micro- level information of miRNAs and drugs to construct multi-view node features from different perspectives. The proposed multi-view graph convolutional network (GCN) encoder obtains miRNA and disease features from different views and learns adaptive importance weights of the embedding using an attention mechanism. Extensive experiments on manually curated benchmark datasets demonstrate that MGCNA outperforms existing baseline methods. Case studies of two common drugs further establish MGCNA's effectiveness in discovering novel MDAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.